The Honey Integrity Act would direct the Secretary of Health and Human Services, acting through FDA, to establish a federal standard of identity for honey within one year of enactment. It also requires a report to Congress within two years on FDA enforcement actions involving adulterated or misbranded honey under the Federal Food, Drug, and Cosmetic Act.
The bill creates a new Honey Integrity Program aimed at detecting economically motivated adulteration in honey sold in interstate commerce. Beginning 180 days after enactment, qualifying commercial honey packers would have to test honey using a combined protocol that can include DNA-based methods, nuclear magnetic resonance, high-resolution mass spectrometry, and other forensic techniques, certify compliance, and report testing results to FDA. If adulteration is identified, packers must report it quickly, refuse the product, and FDA would be required to investigate, test, destroy adulterated honey after confirmation, and share data with federal, state, local, and industry stakeholders. The bill also authorizes FDA to publish a list of qualifying packers, coordinate with Customs and Border Protection and USDA, and collect fees from covered packers to help fund the program.
The bill would add a new federal regulatory framework for honey under the Federal Food, Drug, and Cosmetic Act, including a formal standard of identity, enhanced testing and reporting obligations, and a federal monitoring program for honey integrity. It would primarily affect commercial honey packers that pay assessments to the National Honey Board, while excluding packers the Secretary determines should not be covered. It also expands interagency coordination among FDA, USDA, and CBP and authorizes fees and appropriations to support enforcement and testing activities.
Based on the bill text and available context, the measure appears to have a generally supportive and bipartisan tone, as shown by its introduction by members from different parties. The stated purpose is consumer protection and market integrity rather than a broader policy dispute. There is no recorded committee debate or vote history in the provided materials, so no formal opposition or support beyond the bill’s sponsors is documented here.
The main points of potential contention are the scope and cost of the testing and compliance regime. Covered packers would face mandatory testing, reporting, certification, and possible fees, which could be viewed as burdensome by industry. Another likely issue is implementation: the bill gives FDA significant discretion to define economically motivated adulteration, set testing protocols, determine exclusions for packers, and specify reporting procedures, which could raise concerns about regulatory flexibility and enforcement standards. Supporters would likely emphasize fraud prevention, consumer confidence, and protection of domestic producers.